Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential

I have covered Tarsus Pharmaceuticals ( TARS ) several times, highlighting the company as a Buy due to the robust growth of Xdemvy. Since my first article one year ago, the stock has risen from $47 to $75, a 60% gainBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee a ...